Physiomics awarded grant for PREDICT-ONC project in precision oncology
Physiomics plc, a leader in mathematical modelling and drug development, announces its latest achievement: securing a grant for the PREDICT-ONC project. This project, funded by ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
Lupin signs agreement for biosimilar Pegfilgrastim in Brazil
Lupin Limited has signed an exclusive distribution and marketing agreement with Biomm SA for biosimilar Pegfilgrastim in Brazil. The Indian pharma company had earlier secured ... Read More
EC approves Pelmeg: Mundipharma’s answer to chemotherapy-induced neutropenia
Mundipharma, a German pharmaceutical company, has achieved a significant milestone with the European Commission (EC)'s approval of Pelmeg, its pegylated biosimilar to Amgen’s Neulasta (pegfilgrastim). ... Read More
Pfizer receives FDA approval for Nivestym, a Neutropenia biosimilar
Pfizer Inc. has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for Nivestym (filgrastim-aafi), a biosimilar to Amgen's Neupogen ... Read More